Abstract P5-02-20: Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial
Kang Wang(Hebei North University), Theodoros Foukakis(Karolinska Institutet), Emmanouil G. Sifakis(Karolinska Institutet), Ana Bosch Campos(Lund University), Ellinor Elinder(Stockholm South General Hospital), Thomas Hatschek(Karolinska University Hospital), Aglaia Schiza(Uppsala University Hospital), Alexios Matikas(Karolinska University Hospital), Erika Isaksson-Friman(Saint Göran Hospital), Jamila Adra(Sahlgrenska University Hospital), Dimitrios Salgkamis(Karolinska Institutet), Edward Azavedo(Karolinska Institutet), Lena Carlsson(University of Gothenburg), Susanne Agartz(Karolinska Institutet), Zakaria Einbeigi, Mats Hellström(Karolinska University Hospital), Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet), Hemming Johansson(Karolinska Institutet), Anne Andersson(Umeå University), Judith Bjöhle(Karolinska University Hospital), Ioannis Zerdes(Karolinska University Hospital), Gyula Pekár(Skåne University Hospital), Ann Charlotte Dreifaldt(Örebro University Hospital), Johan Hartman(Karolinska University Hospital), Sara Margolin(University of Copenhagen), Yajing Zhu(Karolinska University Hospital)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k